Posted by Michael Wonder on 03 Jul 2024
Formulary coverage of brand name adalimumab and biosimilars across Medicare Part D plans
2 July 2024 - Adalimumab (Humira) is a top-selling drug in Medicare Part D, representing $4.7 billion of Medicare spending in 2021.
This study examined Part D formulary coverage of adalimumab biosimilars relative to Humira.
